首页> 美国卫生研究院文献>EJIFCC >Case Report: Biliary Pancreatitis With Acute Cholangitis in a Patient Under Anticoagulant Treatment With Dabigatran
【2h】

Case Report: Biliary Pancreatitis With Acute Cholangitis in a Patient Under Anticoagulant Treatment With Dabigatran

机译:病例报告:接受达比加群抗凝治疗的患者的胆源性胰腺炎合并急性胆管炎

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We report a case of acute onset of a biliary pancreatitis with cholangitis presented in our emergency department. The patient was under anticoagulant therapy with dabigatran due to persistent atrial fibrillation. Pancreatic enzymes including lipase were elevated above the linear measuring range and bilirubin together with cholestasis enzymes was also highly elevated. An ERCP with papillotomy was urgently indicated because postponing could lead to further deterioration of the patient's condition. Coagulation testing showed a prolonged thrombin time above 160sec which was followed by a diluted thrombin time (Haemoclot Test) resulted in a peak-level of dabigatran thus confirming full anticoagulation. Therefore, idarucizumab (Praxbind®) was administered pre-procedural of ERCP, the patient underwent uneventful ERCP without any bleeding complications, a full recovery was achieved and the patient was scheduled for elective cholecystectomy.
机译:我们在急诊科报告了胆管炎合并胆源性胰腺炎的急性发作病例。由于持续性房颤,该患者接受达比加群抗凝治疗。包括脂肪酶在内的胰酶升高到线性测量范围之上,胆红素和胆汁淤积酶也升高。急诊建议采用带乳头切开术的ERCP,因为推迟治疗可能会导致患者病情进一步恶化。凝血测试显示凝血酶时间延长到160秒以上,然后凝血酶时间稀释(血凝试验)导致达比加群达到峰值水平,从而证实了完全抗凝。因此,在ERCP术前对idarucizumab(Praxbind ®)进行了治疗,对患者进行了平稳的ERCP,没有任何出血并发症,患者完全康复,并计划进行择期胆囊切除术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号